Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer

More than 90% of patients with locally advanced disease are not eligible for surgery

- PMLiVE

International study reveals 11 new genes linked to aggressive prostate cancer

Findings from the study could improve treatment options for patients with prostate cancer

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

regeneron headquarters

Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma

The regulator is expected to make a decision on the drug by the end of March 2024

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

New diagnosis pathway has been launched to mark European Myeloma Day

The Myeloma Diagnosis Pathway aims to improve early diagnosis for patients

- PMLiVE

Cancer Research UK partners with French cancer institute

Both organisations will support the global Cancer Grand Challenges initiative

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

- PMLiVE

ICR and Merck renew strategic alliance for development of new cancer drugs

The latest agreement builds on 20 years of collaboration between the two partners

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links